

Matteo Lambertini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8041626/matteo-lambertini-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

220
papers

4,708
citations

34
h-index

60
g-index

261
ext. papers

6,704
ext. citations

5.5
avg, IF

6.09
L-index

#	Paper	IF	Citations
220	A retrospective study evaluating the impact of scattering radiation from imaging procedures on oocyte quality during ovarian stimulation for fertility preservation in young breast cancer patients.. <i>Breast Cancer Research and Treatment</i> , 2022 , 192, 123	4.4	
219	Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.. <i>Human Reproduction Update</i> , 2022 ,	15.8	2
218	Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients.. <i>Breast Cancer Research and Treatment</i> , 2022 , 192, 457	4.4	0
217	Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer.. <i>JCO Global Oncology</i> , 2022 , 8, e2100153	3.7	0
216	Installing oncofertility programs for breast cancer in limited versus optimum resource settings: Empirical data from 39 surveyed centers in Repro-Can-OPEN Study Part I & II.. <i>Journal of Assisted Reproduction and Genetics</i> , 2022 , 39, 505	3.4	1
215	The neglected members of the family: non-BRCA mutations in the Fanconi anemia/BRCA pathway and reproduction.. <i>Human Reproduction Update</i> , 2022 ,	15.8	1
214	Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene.. <i>Scientific Reports</i> , 2022 , 12, 1658	4.9	0
213	Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial.. <i>Tumori</i> , 2022 , 3008916211067568	1.7	
212	Hormonal Suppression for Ovarian Protection 2022 , 85-95		
211	Diagnostic and predictive accuracy of anti-müllerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer.. <i>Breast Cancer Research and Treatment</i> , 2022 , 1	4.4	1
210	Abstract PD5-06: Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline BRCA pathogenic variants having a pregnancy after breast cancer. <i>Cancer Research</i> , 2022 , 82, PD5-06-PD5-06	10.1	
209	Abstract P3-09-03: Single nucleotide polymorphisms of aromatase gene (CYP19A1) and toxicity of adjuvant aromatase inhibitors: A translational, prospective study. <i>Cancer Research</i> , 2022 , 82, P3-09-03-P3-09-03	10.1	
208	Abstract P1-18-11: Analysis of first-line (1L) patients (pts) with de novo disease vs late relapse and all pts with vs without prior chemotherapy (CT) in the MONALEESA-3 (ML-3) trial. <i>Cancer Research</i> , 2022 , 82, P1-18-11-P1-18-11	10.1	
207	Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.. <i>Expert Opinion on Investigational Drugs</i> , 2022 , 1-25	5.9	2
206	Breast cancer patients' experience and wishes regarding communication on sexual health: the BEROSE study.. <i>Cancer Investigation</i> , 2022 , 1-15	2.1	0
205	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry.. <i>European Journal of Cancer</i> , 2022 , 170, 10-16	7.5	1
204	Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis. <i>ESMO Open</i> , 2022 , 7, 100501	6	0

203	Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2021 , 1	4.4	8
202	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology, The</i> , 2021 , 22, 1669-1680	21.7	20
201	Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021 , 159, 154-166	7.5	4
200	Adding a platinum agent to neoadjuvant chemotherapy for triple negative breast cancer: the end of the debate. <i>Annals of Oncology</i> , 2021 ,	10.3	5
199	Long-Term Outcomes with Pharmacological Ovarian Suppression during Chemotherapy in Premenopausal Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	2
198	Immunotherapy for cancer treatment during pregnancy. <i>Lancet Oncology, The</i> , 2021 , 22, e550-e561	21.7	3
197	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. <i>ESMO Open</i> , 2021 , 6, 100300	6	1
196	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211053416	5.4	0
195	The impact of COVID-19 on oncology professionals-one year on: lessons learned from the ESMO Resilience Task Force survey series.. <i>ESMO Open</i> , 2021 , 7, 100374	6	6
194	Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021 ,	7.5	18
193	Impact of ARTs on oncological outcomes in young breast cancer survivors. <i>Human Reproduction</i> , 2021 , 36, 381-389	5.7	3
192	Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 462-470	9.7	6
191	Impact of HIV infection on baseline characteristics and survival of women with breast cancer. <i>Aids</i> , 2021 , 35, 605-618	3.5	8
190	CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13535	4.6	3
189	The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration. <i>ESMO Open</i> , 2021 , 6, 100058	6	18
188	T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. <i>ESMO Open</i> , 2021 , 6, 100099	6	7
187	Use of GnRH Analogs for Prevention of Chemotherapy-Induced Gonadotoxicity 2021 , 171-181		
186	Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. <i>ESMO Open</i> , 2021 , 6, 100104	6	5

185	CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , 2021 , 6, 100091	6	5
184	Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13604	4.6	5
183	Final analysis of the PROMISE-GIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 516-516	2.2	2
182	Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women. <i>Breast Cancer: Targets and Therapy</i> , 2021 , 13, 341-351	3.9	0
181	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021 , 148, 76-91	7.5	10
180	The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 524-524	2.2	0
179	Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2016-2024	2.2	10
178	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 82	7.8	0
177	The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 690320	5.3	6
176	VISTA: A Promising Target for Cancer Immunotherapy?. <i>ImmunoTargets and Therapy</i> , 2021 , 10, 185-200	9	5
175	Exclusive endocrine therapy or partial breast irradiation for women aged ≥ 70 years with luminal A-like early stage breast cancer (NCT04134598 - EUROPA): Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome measures. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 182-189	3.6	10
174	Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer. <i>Cancer</i> , 2021 , 127, 1021-1028	6.4	7
173	Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 241-250	3.5	3
172	Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variants. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103201	7	10
171	Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 181-189	7.3	3
170	Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. <i>European Journal of Cancer</i> , 2021 , 144, 351-359	7.5	
169	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. <i>Npj Breast Cancer</i> , 2021 , 7, 16	7.8	3
168	Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments. <i>European Journal of Cancer</i> , 2021 , 144, 310-316	7.5	14

167	ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib. <i>ESMO Open</i> , 2021 , 6, 100018	6	
166	Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. <i>Lancet Oncology, The</i> , 2021 , 22, e303-e313	21.7	26
165	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3293-3305	2.2	14
164	Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 99	7.8	2
163	Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 163, 103365	7	15
162	The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II. <i>ESMO Open</i> , 2021 , 6, 100199	6	9
161	Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment. <i>Cancers</i> , 2021 , 13,	6.6	6
160	Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021 , 11, 686625	5.3	1
159	Reproductive issues in carriers of germline pathogenic variants in the BRCA1/2 genes: an expert meeting. <i>BMC Medicine</i> , 2021 , 19, 205	11.4	9
158	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
157	How to Protect Ovarian Function before and during Chemotherapy?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
156	Response to letter entitled: Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021 , 155, 303-306	7.5	1
155	Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic. <i>British Journal of Cancer</i> , 2021 , 125, 1486-1493	8.7	4
154	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 1458-1467	21.7	7
153	Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review. <i>ESMO Open</i> , 2021 , 6, 100376	3	
152	Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers. <i>In Vivo</i> , 2021 , 35, 635-639	2.3	0
151	Update on the Management of Breast Cancer during Pregnancy. <i>Cancers</i> , 2020 , 12,	6.6	7
150	Highlights from ABC5: Bridging the Gap. <i>Breast Care</i> , 2020 , 15, 75-81	2.4	

149	Call for ensuring cancer care continuity during COVID-19 pandemic. <i>ESMO Open</i> , 2020 , 5, e000783	6	18
148	Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13315	4.6	21
147	Breast cancer screening of mutation carriers in the era of COVID-19 pandemic. <i>International Journal of Cancer</i> , 2020 , 147, 3574-3575	7.5	1
146	Tumor-to-nipple Distance Should Not Preclude Nipple-sparing Mastectomy in Breast Cancer Patients. Personal Experience and Literature Review. <i>Anticancer Research</i> , 2020 , 40, 3543-3550	2.3	4
145	Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in : A Review of Secondary Prevention Guidelines. <i>Journal of Oncology</i> , 2020 , 2020, 9873954	4.5	8
144	Is HER2-positive metastatic breast cancer still an incurable disease?. <i>Lancet Oncology, The</i> , 2020 , 21, 471-477	4.7	4
143	Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. <i>British Journal of Cancer</i> , 2020 , 122, 1611-1617	8.7	4
142	Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle area. <i>European Radiology</i> , 2020 , 30, 4234-4241	8	3
141	Call for assessing treatment-induced gonadotoxicity of platinum-based chemotherapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 239-240	4.4	3
140	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020 , 136, 43-51	7.5	3
139	Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities. <i>JCO Oncology Practice</i> , 2020 , 16, e1304-e1314	2.3	26
138	Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2020 , 14, 1179554920931816	1.8	2
137	Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?. <i>Translational Oncology</i> , 2020 , 13, 100811	4.9	13
136	It Is Time to Talk About Fertility and Immunotherapy. <i>Oncologist</i> , 2020 , 25, 277-278	5.7	26
135	Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 149, 102940	7	3
134	Gender-specific aspects related to type of fertility preservation strategies and access to fertility care. <i>ESMO Open</i> , 2020 , 5, e000771	6	5
133	special series on new emerging targets in cancer immunotherapy. <i>ESMO Open</i> , 2020 , 4, e000795	6	
132	Fertility and Pregnancy Counseling of Breast Cancer Patients with Germline BRCA Mutations 2020 , 131-147		

131	Fertility Preservation and Pregnancy After Breast Cancer 2020 , 167-176		1
130	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. <i>International Journal of Cancer</i> , 2020 , 147, 160-169	7.5	6
129	T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. <i>Clinical Breast Cancer</i> , 2020 , 20, e181-e187	3	24
128	Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2020 , 126, 65-73	7.5	27
127	Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2020 , 31, 1664-1678	10.3	95
126	Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients. <i>Breast Cancer: Basic and Clinical Research</i> , 2020 , 14, 1178223420954179	2.2	9
125	Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study. <i>ESMO Open</i> , 2020 , 5,	6	1
124	Clinical utility of genomic signatures in young breast cancer patients: a systematic review. <i>Npj Breast Cancer</i> , 2020 , 6, 46	7.8	8
123	Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA. <i>Journal of Oncology</i> , 2020 , 2020, 6384190	4.5	13
122	Pregnancy After Breast Cancer in Patients With Germline Mutations. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3012-3023	2.2	33
121	Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial. <i>ESMO Open</i> , 2020 , 5, e000979	6	1
120	ESHRE guideline: female fertility preservation. <i>Human Reproduction Open</i> , 2020 , 2020, hoaa052	6.1	75
119	Reply to S. A. Narod et al. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4352-4354	2.2	2
118	Radiomics and "radi-omics" in cancer immunotherapy: a guide for clinicians. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 154, 103068	7	7
117	Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020 , 10, 574669	5.3	14
116	Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. <i>ESMO Open</i> , 2020 , 5,	6	9
115	Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. <i>European Journal of Cancer</i> , 2020 , 139, 43-50	7.5	147
114	Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1258-1267	2.2	19

113	A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 161-171	4.4	16
112	Tamoxifen Exposure during Pregnancy: A Systematic Review and Three More Cases. <i>Breast Care</i> , 2020 , 15, 148-156	2.4	13
111	Lucitanib for the Treatment of HR/HER2 Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020 , 26, 354-363	12.9	19
110	Highlights from the San Antonio Breast Cancer Symposium (SABCS) 2019. <i>Breast Care</i> , 2020 , 15, 192-196	2.4	
109	Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. <i>Annals of Oncology</i> , 2019 , 30, 1601-1612	10.3	66
108	Implementing the hub and spoke model for the oncofertility units. <i>Breast</i> , 2019 , 48, 100	3.6	4
107	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 103-114	4.4	17
106	Reply to V. Turan et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 86-88	2.2	4
105	Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?. <i>Clinical Medicine Insights Reproductive Health</i> , 2019 , 13, 1179558119828393	6.5	13
104	Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919827714	5.4	17
103	Radiation therapy for young women with early breast cancer: Current state of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 137, 143-153	7	8
102	EUropean REcommendations for female FERtility preservation (EU-REFER): A joint collaboration between oncologists and fertility specialists. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 138, 233-240	7	28
101	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 86-94	9.7	49
100	Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review. <i>Clinical Medicine Insights Reproductive Health</i> , 2019 , 13, 1179558119864584	6.5	15
99	Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. <i>International Journal of Women's Health</i> , 2019 , 11, 431-437	2.8	61
98	Impact of Taxanes, Endocrine Therapy, and Deleterious Germline Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy. <i>Frontiers in Oncology</i> , 2019 , 9, 575	5.3	28
97	Beyond fertility preservation: role of the oncofertility unit in the reproductive and gynecological follow-up of young cancer patients. <i>Human Reproduction</i> , 2019 , 34, 1462-1469	5.7	23
96	Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. <i>Annals of Oncology</i> , 2019 , 30, 1784-1795	10.3	57

95	Oncofertility counselling in premenopausal women with HER2-positive breast cancer. <i>Oncotarget</i> , 2019 , 10, 926-929	3.3	4
94	Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 25	8.3	20
93	How I treat metastatic triple-negative breast cancer. <i>ESMO Open</i> , 2019 , 4, e000504	6	36
92	Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	9
91	Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer. <i>Current Opinion in Oncology</i> , 2019 , 31, 43-51	4.2	5
90	Fertility, sexuality and cancer in young adult women. <i>Current Opinion in Oncology</i> , 2019 , 31, 259-267	4.2	14
89	Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 27-37	4.4	25
88	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. <i>Reproductive BioMedicine Online</i> , 2019 , 38, 835-844	4	17
87	Reply to the letter "Safety of fertility preservation in women with breast cancer". <i>Breast</i> , 2019 , 43, 149-150	1	1
86	Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. <i>Cancer</i> , 2019 , 125, 307-316	6.4	44
85	Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application. <i>Cancer Treatment Reviews</i> , 2019 , 72, 65-77	14.4	54
84	Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Breast</i> , 2018 , 39, 14-18	3.6	12
83	Cyclin-dependent kinase (CDK) inhibitors for hormone receptor-positive advanced breast cancer. <i>The Cochrane Library</i> , 2018 ,	5.2	2
82	How reliable are the available safety data on hormonal stimulation for fertility preservation in young women with newly diagnosed early breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 773-774	4.4	9
81	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 631-638	4.4	35
80	Breast Cancer in Special Groups: Breast Cancer in Pregnancy 2018 , 511-520		
79	Fertility Preservation in Women with Breast Cancer 2018 , 521-527		
78	Response. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 919-920	9.7	2

77	ESMO Leaders Generation Programme: an alumni insight. <i>ESMO Open</i> , 2018 , 3, e000312		6
76	Reply to the letter "Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association". <i>Breast</i> , 2018 , 39, 151-152 ^{3,6}		
75	Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. <i>Annals of Oncology</i> , 2018 , 29, 237-243	10.3	65
74	Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 426-429	9.7	95
73	Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 245-246	4.4	3
72	Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations. <i>Npj Breast Cancer</i> , 2018 , 4, 23	7.8	12
71	Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2018 , 29, 1497-1508	10.3	164
70	Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018 , 62, 123-132	14.4	14
69	Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. <i>Breast</i> , 2018 , 37, 142-147	3.6	20
68	Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1981-1990	2.2	172
67	Adherence to guidelines in requesting Oncotype DX in a publicly funded health care system. <i>Current Oncology</i> , 2018 , 25, e311-e318	2.8	2
66	Management of young women with early breast cancer. <i>ESMO Open</i> , 2018 , 3, e000458	6	10
65	Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences. <i>Cancer Biology and Medicine</i> , 2018 , 15, 6-13	5.2	21
64	Another step towards improving oncofertility counselling of young women with Hodgkin's lymphoma. <i>Lancet Oncology</i> , 2018 , 19, 1264-1266	21.7	4
63	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. <i>Breast</i> , 2018 , 42, 41-49	3.6	49
62	Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 629-649	3.5	20
61	Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERTility (PREFER) study. <i>Breast</i> , 2018 , 41, 51-56	3.6	26
60	Single-agent PARP inhibitors for the treatment of patients with -mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , 2018 , 3, e000361	6	41

59	Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017 , 18, 4	5.4	13
58	Methods of controlled ovarian stimulation for embryo/oocyte cryopreservation in breast cancer patients. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017 , 2, 47-59		8
57	Pharmacotherapy to protect ovarian function and fertility during cancer treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 739-742	4	9
56	State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature. <i>Cancer Treatment Reviews</i> , 2017 , 57, 50-57	14.4	37
55	Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study. <i>Clinical Breast Cancer</i> , 2017 , 17, 601-610.e2	3	23
54	Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2017 , 57, 8-15	14.4	49
53	Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art. <i>Current Opinion in Oncology</i> , 2017 , 29, 243-252	4.2	55
52	Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis. <i>Breast</i> , 2017 , 33, 104-108	3.6	14
51	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017 , 71, 34-42	7.5	31
50	Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. <i>European Journal of Cancer</i> , 2017 , 71, 25-33	7.5	68
49	Debated Role of Ovarian Protection With Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Women With Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 804-805	2.2	18
48	Fertility and pregnancy issues in BRCA-mutated breast cancer patients. <i>Cancer Treatment Reviews</i> , 2017 , 59, 61-70	14.4	51
47	Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. <i>Breast</i> , 2017 , 35, 142-150	3.6	66
46	Breast cancer treatment-induced cardiotoxicity. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 1021-1038	4.1	28
45	The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients. <i>BMC Cancer</i> , 2017 , 17, 346	4.8	19
44	Nail involvement as a negative prognostic factor in biological therapy for psoriasis: a retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 843-846	4.6	20
43	Adjuvant trastuzumab: a 10-year overview of its benefit. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 61-74	3.5	29
42	Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study. <i>Oncotarget</i> , 2017 , 8, 44800-44810	3.3	0

41	Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. <i>OncoTargets and Therapy</i> , 2017 , 10, 3363-3372	4.4	8
40	Fertility Issues in Patients with Breast Cancer or Survivors 2017 , 729-737		
39	Viable Options for Fertility Preservation in Breast Cancer Patients: A Focus on Latin America. <i>Revista De Investigacion Clinica</i> , 2017 , 69, 103-113	1.6	8
38	Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial. <i>Supportive Care in Cancer</i> , 2016 , 24, 1285-94	3.9	12
37	Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 1153-61	3.8	7
36	Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. <i>Cancer Treatment Reviews</i> , 2016 , 49, 65-76	14.4	115
35	Twenty years of anti-HER2 therapy-associated cardiotoxicity. <i>ESMO Open</i> , 2016 , 1, e000073	6	49
34	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. <i>British Journal of Cancer</i> , 2016 , 115, 1471-1478	8.7	29
33	Reply to the letter to the editor Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients? by Rodriguez-Wallberg et al. <i>Annals of Oncology</i> , 2016 , 27, 548-9	10.3	8
32	Fertility preservation in BRCA-mutated breast cancer patients. <i>Breast Cancer Management</i> , 2016 , 5, 61-68.	7	6
31	News on the medical treatment of young women with early-stage HER2-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1643-55	4	7
30	Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?. <i>European Journal of Cancer</i> , 2016 , 54, 163-164	7.5	3
29	Follow-up strategies for women treated for early breast cancer. <i>The Cochrane Library</i> , 2016 , CD001768	5.2	32
28	Cancer and fertility preservation: international recommendations from an expert meeting. <i>BMC Medicine</i> , 2016 , 14, 1	11.4	320
27	Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review. <i>Cancer Treatment Reviews</i> , 2016 , 45, 38-45	14.4	56
26	New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients. <i>Cancer Treatment Reviews</i> , 2016 , 42, 18-23	14.4	10
25	What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities. <i>PLoS ONE</i> , 2016 , 11, e0159146	3.7	2
24	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016 , 1, e000107	6	8

23	Treatment with aromatase inhibitors and markers of cardiovascular disease. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 261-267	4.4	4
22	Exploring the safety of chemotherapy for treating breast cancer during pregnancy. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 1395-408	4.1	15
21	Targeted agents for cancer treatment during pregnancy. <i>Cancer Treatment Reviews</i> , 2015 , 41, 301-9	14.4	61
20	Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 1799-817	5.4	15
19	Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. <i>Annals of Oncology</i> , 2015 , 26, 2408-19	10.3	149
18	Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. <i>Oncologist</i> , 2015 , 20, 880-9	5.7	24
17	Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate?. <i>Oncologist</i> , 2015 , 20, 1233-5	5.7	31
16	Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis. <i>Obstetrics and Gynecology</i> , 2015 , 126, 901	4.9	17
15	Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence. <i>Tumori</i> , 2015 , 101, 398-403	1.7	4
14	Update on fertility preservation in young women undergoing breast cancer and ovarian cancer therapy. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015 , 27, 98-107	2.4	31
13	Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2632-40	27.4	138
12	Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients. <i>Annals of Oncology</i> , 2015 , 26, vi1	10.3	26
11	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2014 , 40, 675-83	14.4	146
10	Strategies for fertility preservation in young early breast cancer patients. <i>Breast</i> , 2014 , 23, 503-10	3.6	38
9	Adjuvant hormonal therapy in young breast cancer patients. <i>Breast Cancer Management</i> , 2014 , 3, 1-4	0.7	2
8	Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients. <i>Endocrine-Related Cancer</i> , 2014 , 21, R51-65	5.7	26
7	The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 89, 112-28	7	70
6	Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 105-105	2.2	7

- 5 Fertility issues in young breast cancer patients: what women want. *Journal of Thoracic Disease*, **2014**, 6, 584-8 2.6 3
- 4 Fertility counseling of young breast cancer patients. *Journal of Thoracic Disease*, **2013**, 5 Suppl 1, S68-80 2.6 13
- 3 Stevens-Johnson syndrome after treatment with bendamustine. *Leukemia Research*, **2012**, 36, e153-4 2.7 11
- 2 Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. *Expert Review of Anticancer Therapy*, **2012**, 12, 1391-405 3.5 16
- 1 Letrozole withdrawal response in locally advanced breast cancer. *Annals of Oncology*, **2011**, 22, 1927-8 10.3 2